Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
RESEARCH TOOLSreports
Holding AUTL?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.21Last Year’s EPS
-$0.44Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -34.76%
|Next Earnings Date:Mar 11, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the FDA approval of AUCATZYL and strong financial positioning to support future growth. While there were increased operating expenses and a regulatory milestone payment, these were largely anticipated and linked to strategic investments and achievements. The sentiment reflects a positive outlook driven by operational and commercial readiness.Company Guidance
During the Q3 2024 earnings call for Autolus Therapeutics, the company provided several key metrics and guidance related to its recent activities and future plans. The approval of AUCATZYL was highlighted as a significant milestone, marking the first CAR T program approved by the FDA without a REMS program. Autolus is in the process of activating 30 centers, reaching 60% of U.S. relapsed or refractory ALL patients, with plans to expand to 60 centers by 2025 to cover 90% of the target population. The manufacturing facility, The Nucleus, has a capacity for approximately 2,000 products annually, with a vein-to-release time of 16 days. The product is priced at $525,000, reflecting its clinical value and differentiated safety profile. Financially, the company reported cash and equivalents of $657.1 million as of September 30, 2024, with net operating expenses of $67.9 million for Q3. Autolus expects to receive a $30 million milestone payment from Blackstone and will make a GBP 10 million regulatory milestone payment to UCLB in Q4. These financial resources are anticipated to support the full commercialization of obe-cel in ALL and pipeline advancements.Approval of AUCATZYL
AUCATZYL received FDA approval, marking a significant milestone for Autolus Therapeutics and providing a new treatment option for patients with relapsed or refractory ALL.
Launch Readiness and Center Onboarding
60 centers in the U.S. are at various stages of onboarding, with 30 ready for activation, covering 60% of the target patient population. Plans to expand to 90% coverage by adding 30 more centers in 2025.
Strong Financial Position
Cash and cash equivalents totaled $657.1 million as of September 30, 2024, up from $239.6 million at the end of December 2023, supporting commercialization and pipeline plans.
Manufacturing Capacity
The Nucleus manufacturing facility in the U.K. supports a capacity of approximately 2,000 products per year, with a target vein-to-release time of 16 days.
Upcoming Milestones
Key presentations planned for the ASH Annual Meeting, and initial data from the Phase I SLE trial expected by the end of Q1 2025.
---
AUTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AUTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.51 | $3.33 | -5.13% |
| Aug 08, 2024 | $4.02 | $3.64 | -9.45% |
| May 17, 2024 | $4.07 | $4.39 | +7.86% |
| Mar 14, 2024 | $5.48 | $5.70 | +4.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Autolus Therapeutics Plc (AUTL) report earnings?
Autolus Therapeutics Plc (AUTL) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Autolus Therapeutics Plc (AUTL) earnings time?
Autolus Therapeutics Plc (AUTL) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUTL EPS forecast?
AUTL EPS forecast for the fiscal quarter 2024 (Q4) is -$0.21.
---